Weiss, L.
Heinrich, K.
Zhang, D.
Dorman, K.
Rühlmann, K.
Hasselmann, K.
Klauschen, F.
Kumbrink, J.
Jung, A.
Rudelius, M.
Mock, A.
Ormanns, Steffen
Kunz, W. G.
Roessler, D.
Beyer, G.
Corradini, S.
Heinzerling, L.
Haas, M.
von Bergwelt-Baildon, M.
Boeck, S.
Heinemann, V.
Westphalen, C. B. http://orcid.org/0000-0002-5310-3754
Funding for this research was provided by:
Universitätsklinik München
Article History
Received: 10 February 2023
Accepted: 2 April 2023
First Online: 16 April 2023
Declarations
:
: LW: Honoraria: Roche, Servier, Travel support: AMGEN. KH: Honoraria: Roche, Taiho; consulting or advisory role: BMS, Servier; travel support and expenses: Amgen, Merck, Servier. DK: Honoraria: AstraZeneca; Travel support: Servier, GSK, and BMS. JK: Honoraria and reimbursement for travel and accommodation for participants in advisory boards and from speaker’s bureau from AstraZeneca, Novartis, Roche Pharma. WGK: Consulting and advisory role: BMS. DR: Honoraria: Bayer, Ipsen; Travel support: Ipsen. LH: Research support from Therakos; speakers and advisory board honoraria from 4SC, Amgen, BiomeDx, Bristol Myers Squibb, Curevac, Merck, Merck Sharp & Dohme, Myoncare, Novartis, Pierre Fabre, Sanofi, SUN and Roche. Patents (a) intra-tumoral administration of IL-12 encoding nucleic acid molecules; Publication No.: WO/2001/052874; PCT/EP2001/000363; (b) preventing secondary lymphedema with vegf-d DNA; Publication No.: WO/2003/093419; PCT/US2003/013350; (c) eosinophil cationic protein (ECP) as a tumor marker for malignant tumors; Publication No.: WO/2019/219705; PCT/EP2019/062378. VH: Honoraria: Merck, Amgen, Roche, Sanofi, SIRTEX, Servier, Pfizer, Pierre-Fabre, AstraZeneca. Consulting: Merck, Amgen, Roche, Sanofi, SIRTEX, BMS; MSD, Novartis, Boehringer Ingelheim, Servier, Pierre-Fabre, Celgene, Terumo. Research funding (for the institution): Merck, Amgen, Roche, Sanofi, Pfizer, Boehringer Ingelheim, Sirtex, Bayer, Servier. Travel accommodation expenses: Merck, Roche, Amgen, SIRTEX, Bayer, Servier. SB: Consulting and advisory role: Celgene, Servier, Incyte, Fresenius, Janssen-Cilag, AstraZeneca, MSD, BMS; Honoraria: Celgene, Servier, MSD. CBW: CBW has received honoraria from Amgen, Bayer, BMS, Chugai, Celgene, Falk, GSK, MSD, Merck, Janssen, Ipsen, Roche, Servier, SIRTeX, Taiho; served on advisory boards for Bayer, BMS, Celgene, Janssen, MSD, Servier, Shire/Baxalta, Rafael Pharmaceuticals, RedHill, Roche; has received travel support by Bayer, Celgene, Janssen, RedHill, Roche, Servier, Taiho and research grants (institutional) by Roche. CBW serves as an officer for European Society of Medical Oncology (ESMO), Deutsche Krebshilfe (DKH), Arbeitsgemeinschaft internistische Onkologie (AIO) and is a member of the EU Commission expert group: Mission Board for cancer.
: This study was conducted with the principles of the Declaration of Helsinki and with the guideline for good clinical practice. The study was approved by the ethic committee of the Medical Faculty of the Ludwig-Maximilians-University Munich (Reference number: 21-0869).